Research Impact

h-index

N/A

Research impact score

Publications

0

Total publications

Trial Results

0

Published trial results

Citations

0

Total citations

Drug Portfolio

MIXED(48)
DRUG(11)
PROCEDURE(3)
BIOLOGICAL(2)
Laboratory Biomarker Analysis
4 trials
phase_1phase_2
university-of-washington
Bone Scan
3 trials
phase_1phase_2
fred-hutchinson-cancer-center, university-of-washington
Quality-of-Life Assessment
3 trials
phase_2
university-of-washington
Questionnaire Administration
3 trials
phase_2
university-of-washington
Computed Tomography
3 trials
phase_1phase_2
university-of-washington, fred-hutchinson-cancer-center
Biospecimen Collection
3 trials
phase_1phase_2
fred-hutchinson-cancer-center, university-of-washington
Fludarabine
2 trials
phase_1phase_1_2
fred-hutchinson-cancer-center
Biopsy Procedure
2 trials
phase_2
university-of-washington, fred-hutchinson-cancer-center

+35 more interventions

43 unique interventions5 categories

Analytics

Trial Phases

Phase 13
Phase 29

Trial Status

Completed2
Recruiting2
Terminated5
Other2

Role Distribution

Principal Investigator11
PI Rate100%

Activity Timeline

Clinical Trials (11)

NCT06145633Phase 2Recruiting
Vorinostat and 177Lu-PSMA-617 for the Treatment of PSMA-Low Metastatic Castration-Resistant Prostate Cancer
Castration-Resistant Prostate CarcinomaMetastatic Prostate AdenocarcinomaStage IVB Prostate Cancer AJCC v8
PrincipalinvestigatorStart date: 2024-09-18
NCT06039371Phase 2Recruiting
Supraphysiological Androgen to Enhance Treatment Activity in Metastatic Castration-Resistant Prostate Cancer, SPECTRA Study
Castration-Resistant Prostate CarcinomaMetastatic Prostate AdenocarcinomaStage IVB Prostate Cancer AJCC v8
PrincipalinvestigatorStart date: 2024-05-21
NCT04951492Phase 2Terminated
Olaparib for the Treatment of Castration Resistant Prostate Adenocarcinoma
Castration-Resistant Prostate CarcinomaProstate Adenocarcinoma
PrincipalinvestigatorStart date: 2022-11-09
NCT04639245Phase 1/2Terminated
Genetically Engineered Cells (MAGE-A1-specific T Cell Receptor-transduced Autologous T-cells) and Atezolizumab for the Treatment of Metastatic Triple Negative Breast Cancer, Urothelial Cancer, or Non-small Cell Lung Cancer
Anatomic Stage IV Breast Cancer AJCC v8Metastatic Lung Non-Small Cell CarcinomaMetastatic Malignant Solid Neoplasm+3 more
PrincipalinvestigatorStart date: 2021-07-19
NCT04336943Phase 2Terminated
Durvalumab and Olaparib for the Treatment of Prostate Cancer in Men Predicted to Have a High Neoantigen Load
Biochemically Recurrent Prostate CarcinomaProstate Adenocarcinoma
PrincipalinvestigatorStart date: 2021-04-13
NCT03999515Phase 2Terminated
Erdafitinib and Abiraterone Acetate or Enzalutamide in Treating Patients With Double Negative Prostate Cancer
Castration-Resistant Prostate CarcinomaDouble-Negative Prostate CarcinomaMetastatic Prostate Carcinoma+4 more
PrincipalinvestigatorStart date: 2020-04-27
NCT02721979Phase 2Terminated
Apalutamide in Treating Patients With Prostate Cancer Who Are in Active Surveillance
Prostate Adenocarcinoma
PrincipalinvestigatorStart date: 2017-11-02
NCT02849990Phase 2Completed
A Phase II Neoadjuvant Study of Apalutamide, Abiraterone Acetate, Prednisone, Degarelix and Indomethacin in Men With Localized Prostate Cancer Pre-prostatectomy
Stage III Prostate Adenocarcinoma AJCC v7Stage III Prostate Cancer AJCC v7Stage IV Prostate Adenocarcinoma AJCC v7+1 more
PrincipalinvestigatorStart date: 2017-03-09
NCT02532114Phase 1Completed
Niclosamide and Enzalutamide in Treating Patients With Castration-Resistant, Metastatic Prostate Cancer
Castration Levels of TestosteroneCastration-Resistant Prostate CarcinomaMetastatic Prostate Carcinoma+2 more
PrincipalinvestigatorStart date: 2015-12-31
NCT02966587Phase 2Withdrawn
Durvalumab in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer
Castration Levels of TestosteroneHormone-Resistant Prostate CancerMicrosatellite Instability
Principalinvestigator

Showing 10 of 11 trials

Research Network

Collaboration Network

1 collaborators·0 connections
Network Legend
KOL
Current Investigator
CO
High-influence Collaborator
CO
Collaborator
Click: view details
Double-click: go to profile
Drag: move node

Similar Key Opinion Leaders

Discover other key opinion leaders with similar research profiles, therapeutic areas, and collaboration networks.

10 similar investigators found

Rahul Aggarwal, MD

University of California, San Francisco

Related
22 trials

Shared therapeutic areas:

Castration-Resistant Prostate CarcinomaMetastatic Malignant Solid NeoplasmProstate Adenocarcinoma+11 more

Worked with same sponsors:

AstraZenecaJanssen Research & Development, LLC+3 more
Similarity Score16%

Jeremie Calais

UCLA / Jonsson Comprehensive Cancer Center

Related
9 trials

Shared therapeutic areas:

Prostate CarcinomaMetastatic Prostate CarcinomaRecurrent Prostate Carcinoma+7 more

Worked with same sponsors:

National Cancer Institute (NCI)
Similarity Score11%

A P Chen

National Cancer Institute LAO

Related
8 trials

Shared therapeutic areas:

Metastatic Malignant Solid NeoplasmAnatomic Stage IV Breast Cancer AJCC v8Castration-Resistant Prostate Carcinoma+4 more

Worked with same sponsors:

National Cancer Institute (NCI)
Similarity Score8%

Amar Kishan

UCLA / Jonsson Comprehensive Cancer Center

Related
7 trials

Shared therapeutic areas:

Prostate AdenocarcinomaStage IVB Prostate Cancer AJCC v8Metastatic Prostate Adenocarcinoma+4 more

Worked with same sponsors:

Janssen Scientific Affairs, LLC
Similarity Score8%

Aung Naing, Md

M.D. Anderson Cancer Center

Related
16 trials

Shared therapeutic areas:

Metastatic Lung Non-Small Cell CarcinomaMetastatic Malignant Solid NeoplasmStage IV Lung Cancer AJCC v8

Worked with same sponsors:

National Cancer Institute (NCI)
Similarity Score3%

Arya Amini

City of Hope Medical Center

Related
7 trials

Shared therapeutic areas:

Stage IV Lung Cancer AJCC v8Metastatic Lung Non-Small Cell Carcinoma

Worked with same sponsors:

National Cancer Institute (NCI)
Similarity Score2%

Aminah Jatoi, MD

Mayo Clinic

Related
29 trials

Shared therapeutic areas:

Metastatic Lung Non-Small Cell CarcinomaStage IV Lung Cancer AJCC v8

Worked with same sponsors:

National Cancer Institute (NCI)
Similarity Score2%

Thomas A Hope, MD

University of California, San Francisco

Related
7 trials

Shared therapeutic areas:

Castration-Resistant Prostate CarcinomaStage IVB Prostate Cancer AJCC v8

Worked with same sponsors:

Novartis
Similarity Score2%

Sriram Yennu

M.D. Anderson Cancer Center

Related
12 trials

Shared therapeutic areas:

Metastatic Malignant Solid NeoplasmStage IV Lung Cancer AJCC v8

Worked with same sponsors:

National Cancer Institute (NCI)
Similarity Score2%

Pamela Munster, MD

University of California, San Francisco

Related
8 trials

Shared therapeutic areas:

Anatomic Stage IV Breast Cancer AJCC v8Metastatic Malignant Solid Neoplasm

Worked with same sponsors:

Novartis
Similarity Score2%

Publications (0)

No publications found for this investigator.

Clinical Trials (11)

Showing 11 of 11 trials

NCT06145633Phase 2PrincipalInvestigator

Vorinostat and 177Lu-PSMA-617 for the Treatment of PSMA-Low Metastatic Castration-Resistant Prostate Cancer

Castration-Resistant Prostate CarcinomaMetastatic Prostate AdenocarcinomaStage IVB Prostate Cancer AJCC v8
Recruiting
NCT06039371Phase 2PrincipalInvestigator

Supraphysiological Androgen to Enhance Treatment Activity in Metastatic Castration-Resistant Prostate Cancer, SPECTRA Study

Castration-Resistant Prostate CarcinomaMetastatic Prostate AdenocarcinomaStage IVB Prostate Cancer AJCC v8
Recruiting
NCT04951492Phase 2PrincipalInvestigator

Olaparib for the Treatment of Castration Resistant Prostate Adenocarcinoma

Castration-Resistant Prostate CarcinomaProstate Adenocarcinoma
Terminated
NCT04639245Phase 1/2PrincipalInvestigator

Genetically Engineered Cells (MAGE-A1-specific T Cell Receptor-transduced Autologous T-cells) and Atezolizumab for the Treatment of Metastatic Triple Negative Breast Cancer, Urothelial Cancer, or Non-small Cell Lung Cancer

Anatomic Stage IV Breast Cancer AJCC v8Metastatic Lung Non-Small Cell CarcinomaMetastatic Malignant Solid Neoplasm+3 more
Terminated
NCT04336943Phase 2PrincipalInvestigator

Durvalumab and Olaparib for the Treatment of Prostate Cancer in Men Predicted to Have a High Neoantigen Load

Biochemically Recurrent Prostate CarcinomaProstate Adenocarcinoma
Terminated
NCT03999515Phase 2PrincipalInvestigator

Erdafitinib and Abiraterone Acetate or Enzalutamide in Treating Patients With Double Negative Prostate Cancer

Castration-Resistant Prostate CarcinomaDouble-Negative Prostate CarcinomaMetastatic Prostate Carcinoma+4 more
Terminated
NCT02721979Phase 2PrincipalInvestigator

Apalutamide in Treating Patients With Prostate Cancer Who Are in Active Surveillance

Prostate Adenocarcinoma
Terminated
NCT02849990Phase 2PrincipalInvestigator

A Phase II Neoadjuvant Study of Apalutamide, Abiraterone Acetate, Prednisone, Degarelix and Indomethacin in Men With Localized Prostate Cancer Pre-prostatectomy

Stage III Prostate Adenocarcinoma AJCC v7Stage III Prostate Cancer AJCC v7Stage IV Prostate Adenocarcinoma AJCC v7+1 more
Completed
NCT02532114Phase 1PrincipalInvestigator

Niclosamide and Enzalutamide in Treating Patients With Castration-Resistant, Metastatic Prostate Cancer

Castration Levels of TestosteroneCastration-Resistant Prostate CarcinomaMetastatic Prostate Carcinoma+2 more
Completed
NCT02966587Phase 2PrincipalInvestigator

Durvalumab in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer

Castration Levels of TestosteroneHormone-Resistant Prostate CancerMicrosatellite Instability
Withdrawn
NCT06094842Phase 1PrincipalInvestigator

Autologous T Cells Lentivirally Transduced to Express L1CAM-Specific Chimeric Antigen Receptors in Treating Patients With Locally Advanced and Unresectable or Metastatic Small Cell Neuroendocrine Prostate Cancer

Prostate CarcinomaProstate Small Cell Neuroendocrine CarcinomaStage III Prostate Cancer AJCC v8+1 more
Withdrawn

All 11 trials loaded